Related references
Note: Only part of the references are listed.VEGF inhibition in urothelial cancer: the past, present and future
Sanaz Ghafouri et al.
WORLD JOURNAL OF UROLOGY (2021)
Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials
Mohammad Abufaraj et al.
EUROPEAN UROLOGY (2021)
Pioneer of prostate cancer: past, present and the future ofFOXA1
Mona Teng et al.
PROTEIN & CELL (2021)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Hormonal Therapy for Prostate Cancer
Kunal Desai et al.
ENDOCRINE REVIEWS (2021)
Isoform-specific Activities of Androgen Receptor and its Splice Variants in Prostate Cancer Cells
Harika Nagandla et al.
ENDOCRINOLOGY (2021)
Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians
Axel S. Merseburger et al.
EUROPEAN UROLOGY (2021)
Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer
Dhruv Bansal et al.
CANCERS (2021)
Cancer Stem Cells-Key Players in Tumor Relapse
Monica Marzagalli et al.
CANCERS (2021)
New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer
Vincenza Conteduca et al.
CELLS (2021)
Optimal treatment sequencing of abiraterone acetate plus prednisone and enzalutamide in patients with castration-resistant metastatic prostate cancer: A systematic review and meta-analysis
J. Cassinello et al.
CANCER TREATMENT REVIEWS (2021)
Relapse of pathological angiogenesis: functional role of the basement membrane and potential treatment strategies
Anthony Mukwaya et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2021)
Progress in Clinical Research on Gonadotropin-Releasing Hormone Receptor Antagonists for the Treatment of Prostate Cancer
Yi-Fu Liu et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2021)
Prostate cancer
Richard J. Rebello et al.
NATURE REVIEWS DISEASE PRIMERS (2021)
Bone Targeting Agents in Patients with Metastatic Prostate Cancer: State of the Art
Veronica Mollica et al.
CANCERS (2021)
Prognostic Significance of Gene Expression and DNA Methylation Markers in Circulating Tumor Cells and Paired Plasma Derived Exosomes in Metastatic Castration Resistant Prostate Cancer
Martha Zavridou et al.
CANCERS (2021)
Role of Gonadotropin-Releasing Hormone (GnRH) in Ovarian Cancer
Carsten Gruendker et al.
CELLS (2021)
The Role of Gonadotropin-Releasing Hormone (GnRH) in Endometrial Cancer
Gunter Emons et al.
CELLS (2021)
Resistance to second-generation androgen receptor antagonists in prostate cancer
Keith T. Schmidt et al.
NATURE REVIEWS UROLOGY (2021)
Current Status and Future Perspectives of Androgen Receptor Inhibition Therapy for Prostate Cancer: A Comprehensive Review
Tae Jin Kim et al.
BIOMOLECULES (2021)
Changing the History of Prostate Cancer with New Targeted Therapies
Susana Hernando Polo et al.
BIOMEDICINES (2021)
Design, synthesis and evaluation of novel enzalutamide analogues as potential anticancer agents
Ritesh P. Bhole et al.
HELIYON (2021)
Endocrine consequences of treatment with the new androgen receptor axis-targeted agents for advanced prostate cancer
Nikolaos Pyrgidis et al.
HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM (2021)
Gonadotropin-Releasing Hormone and GnRH Receptor: Structure, Function and Drug Development
Haralambos Tzoupis et al.
CURRENT MEDICINAL CHEMISTRY (2020)
Androgen Receptor Splice Variant, AR-V7, as a Biomarker of Resistance to Androgen Axis-Targeted Therapies in Advanced Prostate Cancer
Tian Zhang et al.
CLINICAL GENITOURINARY CANCER (2020)
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study
Emmanuel S. Antonarakis et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Comprehensive Analysis of AR Alterations in Circulating Tumor DNA from Patients with Advanced Prostate Cancer
Elisa M. Ledet et al.
ONCOLOGIST (2020)
Optimized functional and structural design of dual-target LMRAP, a bifunctional fusion protein with a 25-amino-acid antitumor peptide and GnRH Fc fragment
Meng Li et al.
ACTA PHARMACEUTICA SINICA B (2020)
Shaping Chromatin States in Prostate Cancer by Pioneer Transcription Factors
William Hankey et al.
CANCER RESEARCH (2020)
Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer
Qi Cao et al.
CLINICAL CANCER RESEARCH (2020)
Cancer stem cell and mesenchymal cell cooperative actions in metastasis progression and hormone resistance in prostate cancer: Potential role of androgen and gonadotropin-releasing hormone receptors (Review)
Hector R. Contreras et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2020)
Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer
Himisha Beltran et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant ARF876L nuclear import and function
Zeyu Wu et al.
PROSTATE (2020)
Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations
Changxue Lu et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2020)
The targeted LHRH analog AEZS-108 alters expression of genes related to angiogenesis and development of metastasis in uveal melanoma
Klara Fodor et al.
Oncotarget (2020)
Recent progress in treating advanced prostate cancer
Theodore Gourdin
CURRENT OPINION IN ONCOLOGY (2020)
The role of extracellular vesicles in prostate cancer with clinical applications
Yu-Ling Tai et al.
ENDOCRINE-RELATED CANCER (2020)
Pharmacotherapeutic strategies for castrate-resistant prostate cancer
Mohamad Moussa et al.
EXPERT OPINION ON PHARMACOTHERAPY (2020)
Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer: a systematic review and meta-analysis
Keiichiro Mori et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2020)
Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer
Amelia Altavilla et al.
EXPERT OPINION ON PHARMACOTHERAPY (2020)
Considerations for the use of gonadotropin-releasing hormone agonists and antagonists in patients with prostate cancer
Hendrik Van Poppel et al.
INTERNATIONAL JOURNAL OF UROLOGY (2020)
Darolutamide: An Evidenced-Based Review of Its Efficacy and Safety in the Treatment of Prostate Cancer
E. David Crawford et al.
CANCER MANAGEMENT AND RESEARCH (2020)
When Less Is More: Specific Capture and Analysis of Tumor Exosomes in Plasma Increases the Sensitivity of Liquid Biopsy for Comprehensive Detection of Multiple Androgen Receptor Phenotypes in Advanced Prostate Cancer Patients
Chiara Foroni et al.
BIOMEDICINES (2020)
Optimizing the management of castration-resistant prostate cancer patients: A practical guide for clinicians
Neal D. Shore et al.
PROSTATE (2020)
Angiogenesis Inhibition in Prostate Cancer: An Update
Chandrani Sarkar et al.
CANCERS (2020)
The Androgen Receptor in Prostate Cancer: Effect of Structure, Ligands and Spliced Variants on Therapy
Elisabeth A. Messner et al.
BIOMEDICINES (2020)
Gonadotropin-Releasing Hormone Receptors in Prostate Cancer: Molecular Aspects and Biological Functions
Fabrizio Fontana et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Observational study on time on treatment with abiraterone and enzalutamide
Giuseppe Fallara et al.
PLOS ONE (2020)
Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications
Gaetano Aurilio et al.
CELLS (2020)
Anti-Angiogenic Therapy in the Treatment of Non-Small Cell Lung Cancer
Wentao Tian et al.
ONCOTARGETS AND THERAPY (2020)
Next-generation androgen receptor inhibitors in non-metastatic castration-resistant prostate cancer
Pernelle Lavaud et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
Angiogenesis in Breast Cancer Progression, Diagnosis, and Treatment
Chikezie O. Madu et al.
JOURNAL OF CANCER (2020)
Regulation of androgen receptor variants in prostate cancer
Yezi Zhu et al.
ASIAN JOURNAL OF UROLOGY (2020)
Comparative assessment of prognostic outcomes between first-generation antiandrogens and novel androgen-receptor-axis-targeted agents in patients with non-metastatic castration-resistant prostate cancer
Hideaki Miyake et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2019)
Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
Karim Fizazi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Ra-223 Treatment for Bone Metastases in Castrate-Resistant Prostate Cancer Practical Management Issues for Patient Selection
Robert B. Den et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2019)
Targeting Angiogenesis in Prostate Cancer
Zsombor Melegh et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
Andrew J. Armstrong et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
GnRH Antagonists Have Direct Inhibitory Effects On Castration-Resistant Prostate Cancer Via Intracrine Androgen and AR-V7 Expression
Vito Cucchiara et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
Ian D. Davis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
Kim N. Chi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Epithelial mesenchymal transition and resistance in endocrine-related cancers
Zoran Culig
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2019)
Second-Generation Antiandrogens: From Discovery to Standard of Care in Castration Resistant Prostate Cancer
Meghan A. Rice et al.
FRONTIERS IN ONCOLOGY (2019)
Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
Qin Feng et al.
FRONTIERS IN ONCOLOGY (2019)
Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer
E. J. Small et al.
ANNALS OF ONCOLOGY (2019)
Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY
Scott T. Tagawa et al.
CLINICAL CANCER RESEARCH (2019)
Targeting Angiogenesis in Colorectal Carcinoma
Anthony Lopez et al.
DRUGS (2019)
Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer
Adam Sharp et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer
Veronica Mollica et al.
CELLS (2019)
Expression pattern of androgen receptors, AR-V7 and AR-567es, in circulating tumor cells and paired plasma-derived extracellular vesicles in metastatic castration resistant prostate cancer
Areti Strati et al.
ANALYST (2019)
A Case of Switching from GnRH Agonist to Antagonist for Castration Resistant Prostate Cancer Control
Rumiko Sugimura et al.
CASE REPORTS IN ONCOLOGY (2019)
Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant prostate cancer
Takayuki Sumiyoshi et al.
SCIENTIFIC REPORTS (2019)
Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases
Heini M. L. Kallio et al.
BRITISH JOURNAL OF CANCER (2018)
Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate Cancer
Michael A. Moses et al.
CANCER RESEARCH (2018)
EVEGF and SEMA4D have synergistic effects on the promotion of angiogenesis in epithelial ovarian cancer
Ying Chen et al.
CELLULAR & MOLECULAR BIOLOGY LETTERS (2018)
Apalutamide and Metastasis-free Survival in Prostate Cancer
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer
Maha Hussain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
Matthew R. Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Histone demethylase JMJD1A promotes alternative splicing of AR variant 7 (AR-V7) in prostate cancer cells
Lingling Fan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13
Zhong Chen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
The androgen receptor malignancy shift in prostate cancer
Ben T. Copeland et al.
PROSTATE (2018)
Prognostic association of plasma cell-free DNA-based androgen receptor amplification and circulating tumor cells in pre-chemotherapy metastatic castration-resistant prostate cancer patients
Manish Kohli et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2018)
Estrogen and Androgen Blockade for Advanced Prostate Cancer in the Era of Precision Medicine
Tetsuya Fujimura et al.
CANCERS (2018)
Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease
Thomas U. Ahearn et al.
CARCINOGENESIS (2018)
Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer
Karim Fizazi et al.
CLINICAL GENITOURINARY CANCER (2018)
Androgen receptor: what we know and what we expect in castration-resistant prostate cancer
Zhonglin Cai et al.
INTERNATIONAL UROLOGY AND NEPHROLOGY (2018)
Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial
Fred Saad et al.
LANCET ONCOLOGY (2018)
Combined androgen blockade achieved better oncological outcome in androgen deprivation therapy for prostate cancer: Analysis of community-based multi-institutional database across Japan using propensity score matching
Mizuki Onozawa et al.
CANCER MEDICINE (2018)
Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer
Chengfei Liu et al.
NATURE COMMUNICATIONS (2018)
Time to progression to castration-resistant prostate cancer after commencing combined androgen blockade for advanced hormone-sensitive prostate cancer
Satoshi Tamada et al.
Oncotarget (2018)
FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist
E. David Crawford et al.
SCANDINAVIAN JOURNAL OF UROLOGY (2018)
Gq-Induced Apoptosis is Mediated by AKT Inhibition That Leads to PKC-Induced JNK Activation
Guy Nadel et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2018)
The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer
Jennifer L. Bishop et al.
CANCER DISCOVERY (2017)
Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer
Timothy N. Clinton et al.
EXPERT OPINION ON PHARMACOTHERAPY (2017)
The Diagnosis and Treatment of Prostate Cancer A Review
Mark S. Litwin et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA
Stephane Oudard et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Clinical Outcomes and Testosterone Levels Following Continuous Androgen Deprivation in Patients with Relapsing or Locally Advanced Prostate Cancer: A Post Hoc Analysis of the ICELAND Study
Bertrand Tombal et al.
JOURNAL OF UROLOGY (2017)
Quercetin Targets hnRNPA1 to Overcome Enzalutamide Resistance in Prostate Cancer Cells
Ramakumar Tummala et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
Karim Fizazi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
N. D. James et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Discovery of LHRH and development of LHRH analogs for prostate cancer treatment
Andrew V. Schally et al.
PROSTATE (2017)
Update of IGF-1 receptor inhibitor (ganitumab, dalotuzumab, cixutumumab, teprotumumab and figitumumab) effects on cancer therapy
Xiao Qu et al.
ONCOTARGET (2017)
Epithelial-mesenchymal transition in prostate cancer: an overview
Micaela Montanari et al.
ONCOTARGET (2017)
The Role of Gonadotropin-Releasing Hormone in Cancer Cell Proliferation and Metastasis
Carsten Gruendker et al.
FRONTIERS IN ENDOCRINOLOGY (2017)
Intrinsic and Regulated Gonadotropin-Releasing Hormone Receptor Gene Transcription in Mammalian Pituitary Gonadotrophs
Marija M. Janjic et al.
FRONTIERS IN ENDOCRINOLOGY (2017)
Crosstalk of the Androgen Receptor with Transcriptional Collaborators: Potential Therapeutic Targets for Castration-Resistant Prostate Cancer
Daisuke Obinata et al.
CANCERS (2017)
A Phase II Trial of AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer
Steven S. Yu et al.
CLINICAL GENITOURINARY CANCER (2017)
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study
V. Conteduca et al.
ANNALS OF ONCOLOGY (2017)
Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer
Giuseppe Galletti et al.
CANCER TREATMENT REVIEWS (2017)
The Role of Angiogenesis in Cancer Treatment
Mehdi Rajabi et al.
BIOMEDICINES (2017)
Peptide-Drug Conjugate GnRH-Sunitinib Targets Angiogenesis Selectively at the Site of Action to Inhibit Tumor Growth
Orestis Argyros et al.
CANCER RESEARCH (2016)
An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer
Axel S. Merseburger et al.
ADVANCES IN THERAPY (2016)
Development of AR-V7 as a putative treatment selection marker for metastatic castration-resistant prostate cancer
Jun Luo
ASIAN JOURNAL OF ANDROLOGY (2016)
Targeting the Bone Microenvironment in Metastatic Castration-Resistant Prostate Cancer
Pavlos Msaouel et al.
CURRENT DRUG TARGETS (2016)
Targeting of Peptide Cytotoxins to LHRH Receptors For Treatment of Cancer
Joerg B. Engel et al.
CURRENT DRUG TARGETS (2016)
Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer
Jonathan Welti et al.
EUROPEAN UROLOGY (2016)
Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort
Matthew R. Smith et al.
EUROPEAN UROLOGY (2016)
The gonadotropin-releasing hormone system: perspectives from reproduction to cancer
Arturo Aguilar-Rojas et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2016)
Androgen receptor splice variant 7 in castration-resistant prostate cancer: Clinical considerations
Alan H. Bryce et al.
INTERNATIONAL JOURNAL OF UROLOGY (2016)
Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial
David F. Penson et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
Nicholas D. James et al.
LANCET (2016)
The Effect of F877L and T878A Mutations on Androgen Receptor Response to Enzalutamide
Stefan Prekovic et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Survival Outcomes of Concurrent Treatment with Docetaxel and Androgen Deprivation Therapy in Metastatic Castration-Resistant Prostate Cancer
Ho Seong Jang et al.
YONSEI MEDICAL JOURNAL (2016)
Targeted suppression of AR-V7 using PIP5K1α inhibitor overcomes enzalutamide resistance in prostate cancer cells
Martuza Sarwar et al.
ONCOTARGET (2016)
Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer
Samanta Salvi et al.
ONCOTARGET (2016)
Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer
Christopher Foley et al.
HORMONES & CANCER (2016)
Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients
Nada Lallous et al.
GENOME BIOLOGY (2016)
Understanding Mechanisms of Resistance in Metastatic Castration-resistant Prostate Cancer: The Role of the Androgen Receptor
Derya Tilki et al.
EUROPEAN UROLOGY FOCUS (2016)
Advances in hormonal therapies for hormone naive and castration-resistant prostate cancers with or without previous chemotherapy
Thy Pham et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2016)
Integrative Clinical Genomics of Advanced Prostate Cancer
Dan Robinson et al.
CELL (2015)
Growth factors mediated cell signalling in prostate cancer progression: Implications in discovery of anti-prostate cancer agents
Gaurav Joshi et al.
CHEMICO-BIOLOGICAL INTERACTIONS (2015)
Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer
Arun A. Azad et al.
CLINICAL CANCER RESEARCH (2015)
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Charles J. Ryan et al.
LANCET ONCOLOGY (2015)
Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer
Sven Perner et al.
ONCOTARGET (2015)
Gonadotropin-releasing hormone antagonists versus standard androgen suppression therapy for advanced prostate cancer A systematic review with meta-analysis
Frank Kunath et al.
BMJ OPEN (2015)
Androgen receptor: structure, role in prostate cancer and drug discovery
M. H. Eileen Tan et al.
ACTA PHARMACOLOGICA SINICA (2015)
Oxime bond-linked daunorubicin-GnRH-III bioconjugates exert antitumor activity in castration-resistant prostate cancer cells via the type I GnRH receptor
Marina Montagnani Marelli et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
In Search of the Molecular Mechanisms Mediating the Inhibitory Effect of the GnRH Antagonist Degarelix on Human Prostate Cell Growth
Monica Sakai et al.
PLOS ONE (2015)
GnRH-Gemcitabine Conjugates for the Treatment of Androgen-Independent Prostate Cancer: Pharmacokinetic Enhancements Combined with Targeted Drug Delivery
Theodoros Karampelas et al.
BIOCONJUGATE CHEMISTRY (2014)
Insulin-like growth factor receptor-1 (IGF-IR) as a target for prostate cancer therapy
Jennifer Wu et al.
CANCER AND METASTASIS REVIEWS (2014)
Phase I, Dose-Escalation Study of the Targeted Cytotoxic LHRH Analog AEZS-108 in Patients with Castration- and Taxane-Resistant Prostate Cancer
Stephen V. Liu et al.
CLINICAL CANCER RESEARCH (2014)
Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer
Kathryn E. Ware et al.
ENDOCRINE-RELATED CANCER (2014)
Visceral Disease in Castration-resistant Prostate Cancer
Carmel J. Pezaro et al.
EUROPEAN UROLOGY (2014)
Functional characteristics of cancer stem cells and their role in drug resistance of prostate cancer
Viviana Castillo et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2014)
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Emmanuel S. Antonarakis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy REPLY
Tomasz M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Mechanisms of the androgen receptor splicing in prostate cancer cells
L. L. Liu et al.
ONCOGENE (2014)
Gonadotropin-Releasing Hormone Agonists Sensitize, and Resensitize, Prostate Cancer Cells to Docetaxel in a p53-Dependent Manner
Roberta M. Moretti et al.
PLOS ONE (2014)
Targeting Hormonal Signaling Pathways in Castration Resistant Prostate Cancer
Marilena Manea et al.
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY (2014)
Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels
Petra Popovics et al.
ONCOTARGET (2014)
Role of the Adjacent Stroma Cells in Prostate Cancer Development and Progression: Synergy between TGF-β and IGF Signaling
Chung Lee et al.
BIOMED RESEARCH INTERNATIONAL (2014)
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
T. M. Beer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The Androgen Receptor in Health and Disease
Takahiro Matsumoto et al.
ANNUAL REVIEW OF PHYSIOLOGY, VOL 75 (2013)
Androgen Receptor Splice Variants Mediate Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cell Lines
Yingming Li et al.
CANCER RESEARCH (2013)
A Road Map to Comprehensive Androgen Receptor Axis Targeting for Castration-Resistant Prostate Cancer
Nicholas Mitsiades
CANCER RESEARCH (2013)
Gonadotropin-releasing hormone receptors as molecular therapeutic targets in prostate cancer: Current options and emerging strategies
Patrizia Limonta et al.
CANCER TREATMENT REVIEWS (2013)
Interactions of the GnRH receptor with heterotrimeric G proteins
Zvi Naor et al.
FRONTIERS IN NEUROENDOCRINOLOGY (2013)
Differential signaling of the GnRH receptor in pituitary gonadotrope cell lines and prostate cancer cell lines
Ludmila Sviridonov et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2013)
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Charles J. Ryan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Intratumoral Conversion of Adrenal Androgen Precursors Drives Androgen Receptor-Activated Cell Growth in Prostate Cancer More Potently Than De Novo Steroidogenesis
Jinpei Kumagai et al.
PROSTATE (2013)
An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)
Manav Korpal et al.
CANCER DISCOVERY (2013)
A Clinically Relevant Androgen Receptor Mutation Confers Resistance to Second-Generation Antiandrogens Enzalutamide and ARN-509
James D. Joseph et al.
CANCER DISCOVERY (2013)
Pharmacoperone IN3 enhances the apoptotic effect of leuprolide in prostate cancer cells by increasing the gonadotropin-releasing hormone receptor in the cell membrane
Catherine A. Sanchez et al.
ANTI-CANCER DRUGS (2012)
GnRH Receptors in Cancer: From Cell Biology to Novel Targeted Therapeutic Strategies
Patrizia Limonta et al.
ENDOCRINE REVIEWS (2012)
AEZS-108: a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors
Joerg Engel et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Gonadotropin-Releasing Hormone Receptor Signaling: Biased and Unbiased
C. A. McArdle
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2012)
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer
Christopher E. Barbieri et al.
NATURE GENETICS (2012)
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Howard I. Scher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Androgen receptor and its splice variants in prostate cancer
Simon Haile et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2011)
Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice Variants
Elahe A. Mostaghel et al.
CLINICAL CANCER RESEARCH (2011)
Novel agents and new therapeutics in castration-resistant prostate cancer
Yichao Wu et al.
CURRENT OPINION IN ONCOLOGY (2011)
Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy
Changmeng Cai et al.
ENDOCRINE-RELATED CANCER (2011)
被撤回的出版物: Gq Protein-induced Apoptosis Is Mediated by AKT Kinase Inhibition That Leads to Protein Kinase C-induced c-Jun N-terminal Kinase Activation (Retracted article. See vol. 292, pg. 8848, 2017)
Ido Ben-Ami et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Efficacy of a Second Line Luteinizing Hormone-Releasing Hormone Agonist After Advanced Prostate Cancer Biochemical Recurrence
Nathan Lawrentschuk et al.
JOURNAL OF UROLOGY (2011)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. De Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Expression of Androgen Receptor Splice Variants in Prostate Cancer Bone Metastases is Associated with Castration-Resistance and Short Survival
Emma Hornberg et al.
PLOS ONE (2011)
Androgen Receptor Variants Occur Frequently in Castration Resistant Prostate Cancer Metastases
Xiaotun Zhang et al.
PLOS ONE (2011)
Elevated GnRH Receptor Expression Plus GnRH Agonist Treatment Inhibits the Growth of a Subset of Papillomavirus 18-Immortalized Human Prostate Cells
Kevin Morgan et al.
PROSTATE (2011)
Integrative Genomic Profiling of Human Prostate Cancer
Barry S. Taylor et al.
CANCER CELL (2010)
Dual Targeting of Tumor and Endothelial Cells by Gonadotropin-Releasing Hormone Agonists to Reduce Melanoma Angiogenesis
Roberta M. Moretti et al.
ENDOCRINOLOGY (2010)
Additional Analysis of the Secondary End Point of Biochemical Recurrence Rate in a Phase 3 Trial (CS21) Comparing Degarelix 80 mg Versus Leuprolide in Prostate Cancer Patients Segmented by Baseline Characteristics
Bertrand Tombal et al.
EUROPEAN UROLOGY (2010)
Systematic Structure-Function Analysis of Androgen Receptor Leu701 Mutants Explains the Properties of the Prostate Cancer Mutant L701H
Dennis J. van de Wijngaart et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant
Shihua Sun et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Use of Analogs of Peptide Hormones Conjugated to Cytotoxic Radicals for Chemotherapy Targeted to Receptors on Tumors
Andrew V. Schally et al.
Current Drug Delivery (2010)
Gonadotropin-releasing hormone type II antagonist induces apoptosis in MCF-7 and triple-negative MDA-MB-231 human breast cancer cells in vitro and in vivo
Carsten Gruendker et al.
BREAST CANCER RESEARCH (2010)
Review of Major Adverse Effects of Androgen-deprivation Therapy in Men With Prostate Cancer
Lockwood G. Taylor et al.
CANCER (2009)
Treatment-Dependent Androgen Receptor Mutations in Prostate Cancer Exploit Multiple Mechanisms to Evade Therapy
Mara P. Steinkamp et al.
CANCER RESEARCH (2009)
GnRH-II Antagonists Induce Apoptosis in Human Endometrial, Ovarian, and Breast Cancer Cells via Activation of Stress-induced MAPKs p38 and JNK and Proapoptotic Protein Bax
Stefanie Fister et al.
CANCER RESEARCH (2009)
Aberrant Activation of Androgen Receptor in a New Neuropeptide-Autocrine Model of Androgen-Insensitive Prostate Cancer
Joy C. Yang et al.
CANCER RESEARCH (2009)
Fluorescence In situ Hybridization Analysis of Circulating Tumor Cells in Metastatic Prostate Cancer
Margaret A. Leversha et al.
CLINICAL CANCER RESEARCH (2009)
Luteinizing hormone-releasing hormone antagonists
Gabor Mezoe et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2009)
Signaling by G-protein-coupled receptor (GPCR): Studies on the GnRH receptor
Zvi Naor
FRONTIERS IN NEUROENDOCRINOLOGY (2009)
Type I Gonadotropin-Releasing Hormone Receptor Mediates the Antiproliferative Effects of GnRH-II on Prostate Cancer Cells
Marina Montagnani Marelli et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Increased Expression of Androgen Receptor Coregulator MAGE-11 in Prostate Cancer by DNA Hypomethylation and Cyclic AMP
Adam R. Karpf et al.
MOLECULAR CANCER RESEARCH (2009)
Luteinizing hormone-releasing hormone receptor-targeted deslorelin-docetaxel conjugate enhances efficacy of docetaxel in prostate cancer therapy
Sneha Sundaram et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Human gonadotropin-releasing hormone receptor-activated cellular functions and signaling pathways in extra-pituitary tissues and cancer cells (Review)
Arturo Aguilar-Rojas et al.
ONCOLOGY REPORTS (2009)
Gonadotropin Releasing Hormone Analogs Induce Apoptosis by Extrinsic Pathway Involving p53 Phosphorylation in Primary Cell Cultures of Human Prostatic Adenocarcinomas
Marisa Clementi et al.
PROSTATE (2009)
DEGARELIX ACETATE FOR THE TREATMENT OF PROSTATE CANCER
Laurence Klotz
DRUGS OF TODAY (2009)
Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family
Jianming Xu et al.
NATURE REVIEWS CANCER (2009)
The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer
Laurence Klotz et al.
BJU INTERNATIONAL (2008)
Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth
R. Bruce Montgomery et al.
CANCER RESEARCH (2008)
Androgen deprivation therapy for prostate cancer
Eric A. Singer et al.
EXPERT OPINION ON PHARMACOTHERAPY (2008)
Gonadotropin-releasing hormone and ovarian cancer: a functional and mechanistic overview
Wai-Kin So et al.
FEBS JOURNAL (2008)
Diversity of actions of GnRHs mediated by ligand-induced selective signaling
Robert P. Millar et al.
FRONTIERS IN NEUROENDOCRINOLOGY (2008)
Gonadotropin-releasing hormone II: a multi-purpose neuropeptide
Johanna S. Schneider et al.
INTEGRATIVE AND COMPARATIVE BIOLOGY (2008)
Androgen receptor (AR) coregulators: A diversity of functions converging on and regulating the AR transcriptional complex
Hannelore V. Heemers et al.
ENDOCRINE REVIEWS (2007)
Expression of GnRH type II is regulated by the androgen receptor in prostate cancer
S. Darby et al.
ENDOCRINE-RELATED CANCER (2007)
Genetic ablation of the amplified-in-breast cancer 1 inhibits spontaneous prostate cancer progression in mice
Arthur C-K. Chung et al.
CANCER RESEARCH (2007)
Structure-activity study on the LH- and FSH-releasing and anticancer effects of gonadotropin-releasing hormone (GnRH)-III analogs
Magdolna Kovacs et al.
PEPTIDES (2007)
Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome
Melanie M. L. Green et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2007)
Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; A possible mechanism of hormone-resistance of prostate cancer cells
Naohiro Fujimoto et al.
CANCER INVESTIGATION (2007)
Gonadotropin-releasing hormone (GnRH) receptors in tumors: a new rationale for the therapeutical application of GnRH analogs in cancer patients?
M. Montagnani Marelli et al.
CURRENT CANCER DRUG TARGETS (2006)
Effect of leuprolide and cetrorelix on cell growth, apoptosis, and GnRH receptor expression in primary cell cultures from human prostate carcinoma
E Castellón et al.
CANCER INVESTIGATION (2006)
Gonadotropin-releasing hormone in apoptosis of prostate cancer cells
S Kraus et al.
CANCER LETTERS (2006)
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer
M Stanbrough et al.
CANCER RESEARCH (2006)
Mechanism of gonadotropin-releasing hormone (GnRH)-I and -II-induced cell growth inhibition in ovarian cancer cells: role of the GnRH-I receptor and protein kinase C pathway
KY Kim et al.
ENDOCRINE-RELATED CANCER (2006)
Gonadotropin-releasing hormone induces actin cytoskeleton remodeling and affects cell migration in a cell-type-specific manner in TSU-Pr1 and DU145 cells
M Enomoto et al.
ENDOCRINOLOGY (2006)
Tumor-secreted vascular endothelial growth factor-C is necessary for prostate cancer lymphangiogenesis, but lymphangiogenesis is unnecessary for lymph node metastasis
SY Wong et al.
CANCER RESEARCH (2005)
Immunohistochemical demonstration of gonadotropin-releasing hormone receptors in prostate carcinoma
J Szabó et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2005)
Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking
QB Wang et al.
MOLECULAR CELL (2005)
GnRHs and GnRH receptors
RP Millar
ANIMAL REPRODUCTION SCIENCE (2005)
Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer
MA Titus et al.
CLINICAL CANCER RESEARCH (2005)
Differential effects of gonadotropin-releasing hormone (GnRH)-I and GnRH-II on prostate cancer cell signaling and death
K Maiti et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer
VJ Gnanapragasam et al.
JOURNAL OF PATHOLOGY (2005)
Molecular biology of gonadotropin-releasing hormone (GnRH)-I, GnRH-1I, and their receptors in humans
CK Cheng et al.
ENDOCRINE REVIEWS (2005)
Luteinising hormone-releasing hormone analogue reverses the cell adhesion profile of EGFR overexpressing DU-145 human prostate carcinoma subline
C Yates et al.
BRITISH JOURNAL OF CANCER (2005)
Chemistry and structural biology of androgen receptor
WQ Gao et al.
CHEMICAL REVIEWS (2005)
Gonadotropin-releasing hormone receptors
RP Millar et al.
ENDOCRINE REVIEWS (2004)
Gonadotropin-releasing hormone induces apoptosis of prostate cancer cells:: Role of c-Jun NH2-terminal kinase, protein kinase B, and extracellular signal-regulated kinase pathways
S Kraus et al.
CANCER RESEARCH (2004)
Gonadotropin-releasing hormone and its receptor in normal and malignant cells
GS Harrison et al.
ENDOCRINE-RELATED CANCER (2004)
Antiproliferative effects of the GnRH antagonist cetrorelix and of GnRH-II on human endometrial and ovarian cancer cells are not mediated through the GnRH type I receptor
C Gründker et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2004)
Gonadotropin-releasing hormone (GnRH) antagonists promote proapoptotic signaling in peripheral reproductive tumor cells by activating a Gαi-coupling state of the type I GnRH receptor
S Maudsley et al.
CANCER RESEARCH (2004)
Newly recognized GnRH receptors: function and relative role
JD Neill et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2004)
Androgen receptor mutations in androgen-in dependent prostate cancer: Cancer and Leukemia Group B Study 9663
ME Taplin et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Inhibitory activity of luteinizing hormone-releasing hormone on tumor growth and progression
RM Moretti et al.
ENDOCRINE-RELATED CANCER (2003)
A transcriptionally active human type II gonadotropin-releasing hormone receptor gene homolog overlaps two genes in the antisense orientation on chromosome 1q.12
K Morgan et al.
ENDOCRINOLOGY (2003)
The role of angiogenesis in prostate development and the pathogenesis of prostate cancer
D Hrouda et al.
UROLOGICAL RESEARCH (2003)
Signalling and anti-proliferative effects mediated by gonadotrophin-releasing hormone receptors after expression in prostate cancer cells using recombinant adenovirus
J Franklin et al.
JOURNAL OF ENDOCRINOLOGY (2003)
GnRH II and type II GnRH receptors
RP Millar
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2003)
Type II gonadotropin-releasing hormone receptor transcripts in human sperm
W van Biljon et al.
BIOLOGY OF REPRODUCTION (2002)
Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells
T Ueda et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer?
F Labrie et al.
UROLOGY (2002)
Signalling, cycling and desensitisation of gonadotrophin-releasing hormone receptors
CA McArdle et al.
JOURNAL OF ENDOCRINOLOGY (2002)
Biology of the gonadotropin-releasing hormone system in gynecological cancers
C Grundker et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2002)
Nuclear receptor coregulators: multiple modes of modification
O Hermanson et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2002)
Intracellular signaling pathways mediated by the gonadotropin-releasing hormone (GnRH) receptor
S Kraus et al.
ARCHIVES OF MEDICAL RESEARCH (2001)
Hypothalamic hormones and cancer
AV Schally et al.
FRONTIERS IN NEUROENDOCRINOLOGY (2001)
Expression of the second isoform of gonadotrophin-releasing hormone (GnRH-II) in human endometrium throughout the menstrual cycle
KW Cheon et al.
MOLECULAR HUMAN REPRODUCTION (2001)
LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action
P Limonta et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2001)
Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer
C Palmberg et al.
JOURNAL OF UROLOGY (2000)
Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor
XY Zhao et al.
NATURE MEDICINE (2000)
High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers
G Halmos et al.
JOURNAL OF UROLOGY (2000)
Expression of the insulin-like growth factor system and cancer progression in hormone-treated prostate cancer patients
K Mita et al.
INTERNATIONAL JOURNAL OF UROLOGY (2000)
Share Paper
